FOR 917: Nanoparticle-based Delivery of Innovative Therapies (NanoTarget)

FOR 917：基于纳米颗粒的创新疗法（NanoTarget）

• 批准号: 40403621
• 金额: --
• 依托单位: Institut für Pharmakologie und Toxikologie
• 依托单位国家: 德国
• 项目类别: Research Units
• 财政年份: 2009
• 资助国家: 德国
• 起止时间: 2008-12-31 至 2015-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/40403621?language=en
• 关键词: 917; Nanoparticle; based; Delivery; Innovative

Gene- and cell-based therapies have great potential for the treatment of human diseases. However, targeting the transfer of genetic material (nucleic acids, viral and non-viral vectors) to specific cells in certain, defined body areas is still a major hurdle for successful gene-based therapies. In addition, targeted positioning of cells in organs of the patient would be required for many cell-based therapies (e.g. stem cells) to achieve efficient accumulation of therapeutic cells in damaged organs. The aim of this Research Unit is the development of nanoparticle-based strategies for targeted transduction and positioning of cells. We will focus on the cardiovascular system, because of its high medical relevance. Furthermore, the cardiovascular continuum is of outmost importance for the delivery of therapies - be it genetic material and/or cells - via the circulation. To achieve non-invasive targeting of genetic material and transduced cells, nanoparticles will be used that are superparamagnetic (magnetic nanoparticles, MNPs). The use of MNPs has the big advantage that these particles and their cargo as well as MNP containing cells can be guided by magnetic fields.

基于基因和细胞的疗法在治疗人类疾病方面具有巨大的潜力。然而，将遗传物质（核酸、病毒和非病毒载体）靶向转移到某些特定身体区域的特定细胞仍然是成功的基因治疗的主要障碍。此外，许多基于细胞的疗法（例如干细胞）需要细胞在患者器官中的靶向定位，以实现治疗性细胞在受损器官中的有效积累。该研究单位的目的是开发基于纳米颗粒的靶向转导和细胞定位策略。我们将重点介绍心血管系统，因为它具有高度的医学相关性。此外，心血管连续体对于通过循环递送治疗-无论是遗传物质和/或细胞-都是最重要的。为了实现遗传物质和转导细胞的非侵入性靶向，将使用超顺磁性纳米颗粒（磁性纳米颗粒，MNP）。MNP的使用具有很大的优点，即这些颗粒及其货物以及含有MNP的细胞可以被磁场引导。